Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Schizophrenia cannabidiol:

Is cannabidiol an effective treatment for schizophrenia? Guinguis R et al. Medwave. (2017)

Does cannabidiol have a role in the treatment of schizophrenia? Gururajan A et al. Schizophr Res. (2016)

A systematic review of the effect of cannabidiol on cognitive function: Relevance to schizophrenia. Osborne AL et al. Neurosci Biobehav Rev. (2017)

Search results

Items: 1 to 20 of 125

1.

Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol.

Makiol C, Kluge M.

Aust N Z J Psychiatry. 2018 Dec 13:4867418815982. doi: 10.1177/0004867418815982. [Epub ahead of print] No abstract available.

PMID:
30543310
2.

Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia.

Stark T, Ruda-Kucerova J, Iannotti FA, D'Addario C, Di Marco R, Pekarik V, Drazanova E, Piscitelli F, Bari M, Babinska Z, Giurdanella G, Di Bartolomeo M, Salomone S, Sulcova A, Maccarrone M, Wotjak CT, Starcuk Z Jr, Drago F, Mechoulam R, Di Marzo V, Micale V.

Neuropharmacology. 2018 Nov 26;146:212-221. doi: 10.1016/j.neuropharm.2018.11.035. [Epub ahead of print]

PMID:
30496751
3.

Translational Investigation of the Therapeutic Potential of Cannabidiol (CBD): Toward a New Age.

Crippa JA, Guimarães FS, Campos AC, Zuardi AW.

Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018. Review.

4.

New Perspectives on the Use of Cannabis in the Treatment of Psychiatric Disorders.

Scherma M, Masia P, Deidda M, Fratta W, Tanda G, Fadda P.

Medicines (Basel). 2018 Oct 2;5(4). pii: E107. doi: 10.3390/medicines5040107. Review.

5.

Cannabinoid Delivery Systems for Pain and Inflammation Treatment.

Bruni N, Della Pepa C, Oliaro-Bosso S, Pessione E, Gastaldi D, Dosio F.

Molecules. 2018 Sep 27;23(10). pii: E2478. doi: 10.3390/molecules23102478. Review.

PMID:
30262735
Free PMC Article
6.

Acceptance of pharmaceutical cannabis substitution by cannabis using patients with schizophrenia.

van Amsterdam J, Vervloet J, de Weert G, Buwalda VJA, Goudriaan AE, van den Brink W.

Harm Reduct J. 2018 Sep 20;15(1):47. doi: 10.1186/s12954-018-0253-7.

7.

Cannabidiol Administered During Peri-Adolescence Prevents Behavioral Abnormalities in an Animal Model of Schizophrenia.

Peres FF, Diana MC, Levin R, Suiama MA, Almeida V, Vendramini AM, Santos CM, Zuardi AW, Hallak JEC, Crippa JA, Abílio VC.

Front Pharmacol. 2018 Aug 21;9:901. doi: 10.3389/fphar.2018.00901. eCollection 2018.

8.

Individual and combined effects of acute delta-9-tetrahydrocannabinol and cannabidiol on psychotomimetic symptoms and memory function.

Morgan CJA, Freeman TP, Hindocha C, Schafer G, Gardner C, Curran HV.

Transl Psychiatry. 2018 Sep 5;8(1):181. doi: 10.1038/s41398-018-0191-x.

9.

The Role of Cannabis within an Emerging Perspective on Schizophrenia.

Diviant JP, Vigil JM, Stith SS.

Medicines (Basel). 2018 Aug 8;5(3). pii: E86. doi: 10.3390/medicines5030086.

10.

Role of the Endocannabinoid System in the Pathophysiology of Schizophrenia: Implications for Pharmacological Intervention.

Leweke FM, Mueller JK, Lange B, Fritze S, Topor CE, Koethe D, Rohleder C.

CNS Drugs. 2018 Jul;32(7):605-619. doi: 10.1007/s40263-018-0539-z.

PMID:
30022465
11.

Evidence for the use of "medical marijuana" in psychiatric and neurologic disorders.

Noel C.

Ment Health Clin. 2018 Mar 23;7(1):29-38. doi: 10.9740/mhc.2017.01.029. eCollection 2017 Jan.

12.

Cannabidiol effects on prepulse inhibition in nonhuman primates.

Saletti PG, Tomaz C.

Rev Neurosci. 2018 May 24. pii: /j/revneuro.ahead-of-print/revneuro-2017-0101/revneuro-2017-0101.xml. doi: 10.1515/revneuro-2017-0101. [Epub ahead of print]

PMID:
29794254
13.

[Current and future pharmacotherapy of severe psychiatric disorders].

Češková E.

Cas Lek Cesk. 2018 Spring;157(2):96-100. Czech.

PMID:
29790360
14.

Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: a critical overview.

Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P.

Epidemiol Psychiatr Sci. 2018 Aug;27(4):327-335. doi: 10.1017/S2045796018000239. Epub 2018 May 23. Review.

PMID:
29789034
15.

Review of the neurological benefits of phytocannabinoids.

Maroon J, Bost J.

Surg Neurol Int. 2018 Apr 26;9:91. doi: 10.4103/sni.sni_45_18. eCollection 2018. Review.

16.

Prolonged Cannabidiol Treatment Effects on Hippocampal Subfield Volumes in Current Cannabis Users.

Beale C, Broyd SJ, Chye Y, Suo C, Schira M, Galettis P, Martin JH, Yücel M, Solowij N.

Cannabis Cannabinoid Res. 2018 Apr 1;3(1):94-107. doi: 10.1089/can.2017.0047. eCollection 2018.

17.

The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial.

Boggs DL, Surti T, Gupta A, Gupta S, Niciu M, Pittman B, Schnakenberg Martin AM, Thurnauer H, Davies A, D'Souza DC, Ranganathan M.

Psychopharmacology (Berl). 2018 Jul;235(7):1923-1932. doi: 10.1007/s00213-018-4885-9. Epub 2018 Apr 5.

PMID:
29619533
18.

Novel treatment options in depression and psychosis.

Ceskova E, Silhan P.

Neuropsychiatr Dis Treat. 2018 Mar 13;14:741-747. doi: 10.2147/NDT.S157475. eCollection 2018. Review.

19.

Cannabidiol, an Adjunct Player in the Antipsychosis Arsenal.

Bassir Nia A, Hurd YL.

Am J Psychiatry. 2018 Mar 1;175(3):197-198. doi: 10.1176/appi.ajp.2017.17121295. No abstract available.

PMID:
29490489
20.

The Influence of DAT1, COMT, and BDNF Genetic Polymorphisms on Total and Subregional Hippocampal Volumes in Early Onset Heavy Cannabis Users.

Batalla A, Lorenzetti V, Chye Y, Yücel M, Soriano-Mas C, Bhattacharyya S, Torrens M, Crippa JAS, Martín-Santos R.

Cannabis Cannabinoid Res. 2018 Feb 1;3(1):1-10. doi: 10.1089/can.2017.0021. eCollection 2018.

Supplemental Content

Loading ...
Support Center